DPP

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. Karagiannis and colleagues conducted a systematic review and meta-analysis of 27 studies to evaluate the efficacy of DPP-4 inhibitors for treatment of type 2 diabetes when compared with other antihyperglycemic therapies.

EASIE: Insulin Glargine vs Sitagliptin in Insulin-naïve Patients with Type 2 Diabetes Uncontrolled on Metformin

Top

Continuous coverage of ADA 2012. Aschner P, Chan J, Owens DR, et al; on behalf of the EASIE investigators. EASIE: Insulin Glargine vs Sitagliptin in Insulin-naïve Patients with Type 2 Diabetes Uncontrolled on Metformin. Lancet. 2012;379(9833):2262-2269. The Evaluation of insulin glargine versus Sitagliptin in Insulin-naïve patients (EASIE) trial is a multicenter, randomized, parallel, open-label trial that examined the efficacy, safety, and tolerability of a basal insulin, insulin glargine, vs a DPP-4 inhibitor, sitagliptin, among insulin-naïve patients with type 2 diabetes that was uncontrolled on metformin.

DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction

Top

Continuous coverage of ADA 2012. Perreault L, Pan Q, Mather KJ, et al; for the Diabetes Prevention Program Research Group. DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction. Lancet. 2012;379(9833):2243-2251. This report sought to quantify and predict diabetes risk reduction during the long-term follow-up to the Diabetes Prevention Program (DPP), the Diabetes Prevention Program Outcomes Study (DPPOS).

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study(2)

Top

Long term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes StudyThe Diabetes Prevention Program Research Group. Diabetes Care. 2012 35 731 737. Results from the Diabetes Prevention Program (DPP) study (a randomized, double-blind trial of metformin or placebo) and its long-term follow-up, the DPP Outcomes Study (DPPOS; an open-label extension of metformin and analysis of adverse events, tolerability, and effects of adherence on weight change and waist circumference) demonstrated a reduction in the development of diabetes among subjects treated with metformin.

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment

Top

Nowicki M, Rychlik I, Haller H, et al. Int J Clin Pract . Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. 2011;65(12):1230-1239. Nowicki and colleagues examined the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, saxagliptin, among patients with inadequately controlled type 2 diabetes and renal impairment in a 52-week study.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting systematic review and meta analysis. BMJ. 2012;344:e1369. doi 10.1136 bmj.e1369. OBJECTIVE: To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors compared with metformin as monotherapy, or with other commonly used hypoglycaemic drugs combined with metformin, in adults with type 2 diabetes mellitus.

1 2 3 4 5 6 Next